These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18664987)

  • 41. No residual activity of raltegravir after development of 148 complex mutations in vivo.
    Khanlou H; Sayana S; Acosta E
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
    [No Abstract]   [Full Text] [Related]  

  • 42. Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice.
    Romano L; Peduzzi C; Venturi G; Di Pietro M; Carli T; Corsi P; Gonnelli A; Valensin PE; Zazzi M
    J Acquir Immune Defic Syndr; 2002 Aug; 30(5):533-5. PubMed ID: 12154345
    [No Abstract]   [Full Text] [Related]  

  • 43. Antiretroviral Resistance Mutations (revised April 2001).
    ;
    HIV Clin Trials; 2001; 2(4):346-55. PubMed ID: 11590539
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical utility of resistance testing.
    Stebbing J; Gazzard BG
    J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
    [No Abstract]   [Full Text] [Related]  

  • 45. Multiclass primary antiretroviral drug resistance in a patient presenting HIV-1/2 dual infection.
    Castro E; Recordon-Pinson P; Cavassini M; Fleury H
    Antivir Ther; 2012; 17(3):593-4. PubMed ID: 22301389
    [No Abstract]   [Full Text] [Related]  

  • 46. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
    Hughes A; Barber T; Nelson M
    J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.
    Tremblay CL; Giguel F; Kollmann C; Guan Y; Chou TC; Baroudy BM; Hirsch MS
    Antimicrob Agents Chemother; 2002 May; 46(5):1336-9. PubMed ID: 11959565
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule.
    Hurt CB
    Antivir Ther; 2011; 16(2):137-40. PubMed ID: 21447861
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia.
    Duval X; Descamps D; Breton G; Darmon S; Ecobichon JL; Delarue S; Peytavin G; Leport C; Vildé JL; Brun-Vézinet F
    Antivir Ther; 2005; 10(1):197-9. PubMed ID: 15751779
    [No Abstract]   [Full Text] [Related]  

  • 50. Graph theory concepts in the rationales of anti HIV-1 compounds.
    Debnath U; Katti SB; Prabhakar YS
    Curr Comput Aided Drug Des; 2013 Dec; 9(4):472-81. PubMed ID: 24138418
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection.
    Cossarini F; Boeri E; Canducci F; Salpietro S; Bigoloni A; Galli L; Spagnuolo V; Castagna A; Clementi M; Lazzarin A; Gianotti N
    J Acquir Immune Defic Syndr; 2011 Feb; 56(2):e51-4. PubMed ID: 21233631
    [No Abstract]   [Full Text] [Related]  

  • 52. Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1.
    Beale KK; Robinson WE
    Antiviral Res; 2000 Jun; 46(3):223-32. PubMed ID: 10867160
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance.
    Nolan M; Fowler MG; Mofenson LM
    J Acquir Immune Defic Syndr; 2002 Jun; 30(2):216-29. PubMed ID: 12045685
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stability of transmitted drug-resistant HIV-1 species.
    Cane PA
    Curr Opin Infect Dis; 2005 Dec; 18(6):537-42. PubMed ID: 16258329
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
    Winters MA; Merigan TC
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2575-82. PubMed ID: 15980322
    [No Abstract]   [Full Text] [Related]  

  • 57. High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.
    Charpentier C; Bellecave P; Cisse M; Mamadou S; Diakite M; Peytavin G; Tchiombiano S; Teisseire P; Pizarro L; Storto A; Brun-Vézinet F; Katlama C; Calvez V; Marcelin AG; Masquelier B; Descamps D
    Antivir Ther; 2011; 16(3):429-33. PubMed ID: 21555827
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New drugs.
    Pozniak A
    J HIV Ther; 2008 Jun; 13(2):27-33. PubMed ID: 18953271
    [No Abstract]   [Full Text] [Related]  

  • 59. Low prevalence of transmitted drug resistance among newly diagnosed HIV-1 patients in Latvia.
    Balode D; Westman M; Kolupajeva T; Rozentale B; Albert J
    J Med Virol; 2010 Dec; 82(12):2013-8. PubMed ID: 20981787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.